Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia.

@article{Aono2009TherapeuticEO,
  title={Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia.},
  author={Yukiko Aono and Yuji Yamazaki and Junichi Yasutake and Takehisa Kawata and Hisashi Hasegawa and Itaru Urakawa and Toshiro Fujita and Michihito Wada and Takeyoshi Yamashita and Seiji Fukumoto and Takashi L Shimada},
  journal={Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research},
  year={2009},
  volume={24 11},
  pages={1879-88}
}
X-linked hypophosphatemia (XLH), characterized by renal phosphate wasting, is the most common cause of vitamin D-resistant rickets. It has been postulated that some phosphaturic factor plays a causative role in XLH and its murine homolog, the Hyp mouse. Fibroblast growth factor 23 (FGF23) is a physiological phosphaturic factor; its circulatory level is known to be high in most patients with XLH and Hyp mice, suggesting its pathophysiological role in this disease. To test this hypothesis, we… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 63 extracted citations

Similar Papers

Loading similar papers…